Healthcare Professionals

COVID-19 and Thalassaemia: A Position Statement of the Thalassaemia International Federation
News

COVID-19 and Thalassaemia: A Position Statement of the Thalassaemia International Federation

Many patients with haemoglobinopathies, including thalassaemia and sickle cell disease, are at increased risk of developing severe complications from the coronavirus disease 2019 (COVID‐19). Although epidemiologic evidence concerning the novel…
TIF Postpones its International Conference on Thalassaemia to 2021
News

TIF Postpones its International Conference on Thalassaemia to 2021

Being mindful of the COVID-19 situation and wanting to ensure participants’ safety, TIF has taken the decision to postpone its long-awaited ’15th International Conference on Thalassaemia & other Haemoglobinopathies‘ & the ’17th TIF…
Coronavirus Disease among Persons with Sickle Cell Disease
Clinical News

Coronavirus Disease among Persons with Sickle Cell Disease

Individuals with sickle cell disease (SCD) are a particularly vulnerable group of patients, with a higher risk of severe complications due to COVID-19 infection than the general public. A recent…
GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (Voxelotor) to Treat Sickle Cell Patients in Europe
Clinical News

GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (Voxelotor) to Treat Sickle Cell Patients in Europe

Global Blood Therapeutics (GBT) plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Oxbryta (Voxelotor) be approved for treating hemolytic anemia in patients with sickle cell disease…
Thalassaemia Prior and Consequent to COVID-19 Pandemic: The Perspective of Thalassaemia International Federation (TIF)
News

Thalassaemia Prior and Consequent to COVID-19 Pandemic: The Perspective of Thalassaemia International Federation (TIF)

Patients with haemoglobin disorders, particularly β-thalassaemia or sickle cell disease (SCD) or combined forms, on account of their underlying disease pathology and associated (iron load mainly in the case of…
Advances in the Care & Cure of Thalassaemia: New Hopes & Challenges
News

Advances in the Care & Cure of Thalassaemia: New Hopes & Challenges

TIF, in collaboration with Thalassemics India and Thalassemia Patients Advovacy Group – India, conducted on June 12, 2020 a Webinar on the novel treatments emerging for thalassaemia and the hopes…
IMR-687 Receives FDA Orphan Drug Designation for the Treatment of β-Τhalassaemia
Clinical News

IMR-687 Receives FDA Orphan Drug Designation for the Treatment of β-Τhalassaemia

IMARA Inc., a clinical-stage biopharmaceutical company operating in the haemoglobin disorders field, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IMR-687 for the…
25th EHA Annual Virtual Congress: TIF Brings you All the Latest Developments on Thalassaemia
News

25th EHA Annual Virtual Congress: TIF Brings you All the Latest Developments on Thalassaemia

TIF was excited to participate in the 25th European Hematology Association (EHA) Annual  Virtual Congress, held this year virtually on 11 – 21 June 2020. Dr Androulla Eleftheriou (TIF Executive…
FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia
Clinical News

FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia

Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s first-in-class pyruvate kinase-R (PKR) activator Mitapivat for the treatment of…
TIF Issues Position Statement in Honour of the World Blood Donor Day 2020
News

TIF Issues Position Statement in Honour of the World Blood Donor Day 2020

There is one thing that definitely makes us heroes: giving blood.  It is a life-saving gesture that any of us in good health should very seriously consider making. Every couple…
Back to top button
Close
Close